GILD:NGS-Gilead Sciences Inc. (USD)

EQUITY | Drug Manufacturers - General | Nasdaq Global Select

Last Closing

USD 65.42

Change

0.00 (0.00)%

Market Cap

USD 98.10B

Volume

0.01B

Analyst Target

USD 77.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.43 (-0.55%)

USD 240.63B
AMGN Amgen Inc

-2.71 (-0.87%)

USD 167.83B
SNY Sanofi ADR

+0.59 (+1.21%)

USD 125.21B
BIIB Biogen Inc

-1.25 (-0.56%)

USD 30.42B
GRFS Grifols SA ADR

+0.06 (+0.86%)

USD 5.44B
AMRN Amarin Corporation PLC

-0.03 (-3.13%)

USD 0.36B
SCLX Scilex Holding Company

-0.08 (-10.21%)

USD 0.10B
MIRA MIRA Pharmaceuticals Inc. Comm..

-0.03 (-4.00%)

USD 0.02B
SCLXW Scilex Holding Company

-0.01 (-2.84%)

N/A

ETFs Containing GILD

UBIO 7.77 % 0.95 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 7.54 % 0.00 %

-0.01 (0.00%)

USD 0.46B
BTEK:LSE iShares Nasdaq US Biotech.. 7.54 % 0.00 %

-0.02 (0.00%)

USD 0.52B
BTEE:LSE iShares Nasdaq US Biotech.. 7.54 % 0.00 %

-0.02 (0.00%)

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 7.43 % 0.00 %

+0.05 (+0.00%)

USD 0.35M
2B70:F iShares NASDAQ US Biotech.. 7.35 % 0.00 %

-0.06 (0.00%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 7.35 % 0.00 %

-0.02 (0.00%)

USD 0.52B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.44 % 0.00 %

+0.15 (+0.00%)

USD 3.48M
XNNV:XETRA Xtrackers MSCI Innovation.. 4.39 % 0.00 %

+0.01 (+0.00%)

USD 7.60M
XGES:LSE Xtrackers MSCI Genomic He.. 4.13 % 0.00 %

+0.13 (+0.00%)

USD 3.48M
XNNS:LSE Xtrackers MSCI Innovation.. 4.00 % 0.00 %

-0.02 (0.00%)

USD 7.60M
XNNV:LSE Xtrackers MSCI Innovation.. 4.00 % 0.00 %

-0.01 (0.00%)

USD 7.60M
JPHC:PA Amundi Index Solutions - .. 3.90 % 0.00 %

+0.38 (+0.00%)

USD 4.09M
JP40:F Amundi Index Solutions - .. 3.90 % 0.00 %

-0.88 (0.00%)

N/A
JP4H:F Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

N/A
JP40:XETRA Amundi Index Solutions - .. 3.90 % 0.00 %

-0.72 (0.00%)

USD 0.05B
JPHG:PA Amundi Index Solutions - .. 3.90 % 0.00 %

+0.83 (+0.00%)

N/A
JPHC:SW Amundi Index Solutions - .. 3.90 % 0.00 %

+0.40 (+0.00%)

USD 4.05M
JPHE:SW Amundi Index Solutions - .. 3.90 % 0.00 %

+0.80 (+0.00%)

USD 0.07B
JPHG:SW Amundi Index Solutions - .. 3.90 % 0.00 %

N/A

USD 2.82M
JPHU:SW Amundi Index Solutions - .. 3.90 % 0.00 %

+0.25 (+0.00%)

USD 0.05B
JPNK:SW Amundi Index Solutions - .. 3.90 % 0.00 %

-0.38 (0.00%)

USD 0.07B
JPNY:SW Amundi Index Solutions - .. 3.90 % 0.00 %

+65.00 (+0.00%)

USD 6.76B
XFVT:LSE Xtrackers FTSE Vietnam Sw.. 3.38 % 0.00 %

-16.00 (0.00%)

USD 0.35B
XVTD:LSE Xtrackers - FTSE Vietnam .. 3.38 % 0.00 %

-0.20 (0.00%)

USD 0.36B
MDLV 3.37 % 0.00 %

N/A

N/A
WHCS:SW iShares MSCI World Health.. 3.18 % 0.00 %

N/A

USD 0.84B
DHS:SW WisdomTree US Equity Inco.. 2.08 % 0.00 %

+0.16 (+0.00%)

N/A
DHSA:SW WisdomTree US Equity Inco.. 2.08 % 0.00 %

+0.57 (+0.00%)

USD 0.29M
WTD9:F WisdomTree US Equity Inco.. 1.96 % 0.00 %

+0.22 (+0.00%)

USD 0.06B
WTDY:F WisdomTree Issuer ICAV - .. 1.96 % 0.00 %

+0.26 (+0.00%)

USD 0.64M
WTEU:F WisdomTree US Equity Inco.. 1.96 % 0.00 %

+0.18 (+0.00%)

USD 0.11B
WTD9:XETRA WisdomTree Issuer ICAV - .. 1.96 % 0.00 %

+0.13 (+0.00%)

USD 0.05B
WTDY:XETRA WisdomTree Issuer ICAV - .. 1.96 % 0.00 %

+0.09 (+0.00%)

USD 0.85M
WTEU:XETRA WisdomTree US Equity Inco.. 1.96 % 0.00 %

+0.10 (+0.00%)

USD 0.11B
DHS:LSE WisdomTree US Equity Inco.. 1.96 % 0.00 %

+14.85 (+0.00%)

USD 0.03B
DHSA:LSE WisdomTree US Equity Inco.. 1.96 % 0.00 %

+0.07 (+0.00%)

USD 0.04B
DHSD:LSE WisdomTree US Equity Inco.. 1.96 % 0.00 %

+0.08 (+0.00%)

USD 0.03B
DHSG:LSE WisdomTree US Equity Inco.. 1.96 % 0.00 %

+7.50 (+0.00%)

USD 0.72M
DHSP:LSE WisdomTree US Equity Inco.. 1.96 % 0.00 %

+6.00 (+0.00%)

USD 0.04B
UBBB:PA Amundi Index Solutions - .. 0.46 % 0.00 %

-0.05 (0.00%)

USD 0.16B
BBH VanEck Biotech ETF 0.00 % 0.35 %

-0.56 (0.00%)

USD 0.41B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.95 (0.00%)

USD 0.08B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.34 (+0.00%)

USD 3.52M
BSCK 0.00 % 0.10 %

N/A

N/A
BSCL 0.00 % 0.10 %

N/A

N/A
BSCQ Invesco BulletShares 2026.. 0.00 % 0.10 %

-0.01 (0.00%)

USD 3.01B
CBND 0.00 % 0.16 %

N/A

N/A
DVP 0.00 % 0.48 %

N/A

N/A
ESGW 0.00 % 0.40 %

N/A

N/A
FCY 0.00 % 0.84 %

N/A

N/A
FCY:CA 0.00 % 0.95 %

N/A

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
FTLS First Trust Long/Short Eq.. 0.00 % 1.59 %

-0.31 (0.00%)

USD 1.13B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-0.02 (0.00%)

USD 6.95B
IBCD 0.00 % 0.10 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.49 (0.00%)

USD 0.23B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

-0.09 (0.00%)

USD 0.02B
IVFVC 0.00 % 0.00 %

N/A

N/A
VALQ American Century STOXX U... 0.00 % 0.29 %

+0.25 (+0.00%)

USD 0.21B
VSL 0.00 % 0.65 %

N/A

N/A
JIGB JPMorgan Corporate Bond R.. 0.00 % 0.14 %

N/A

USD 0.05B
SPBO SPDR Portfolio Corporate .. 0.00 % 0.00 %

-0.07 (0.00%)

USD 1.40B
RJZ 0.00 % 0.75 %

N/A

N/A
SCIU 0.00 % 0.19 %

N/A

N/A
SICK 0.00 % 0.95 %

N/A

N/A
XMS:CA iShares Edge MSCI Min Vol.. 0.00 % 0.33 %

+0.24 (+0.00%)

CAD 0.04B
ZBIO 0.00 % 0.95 %

N/A

N/A
FCW:CA 0.00 % 0.90 %

N/A

N/A
MINV:LSE iShares VI Public Limited.. 0.00 % 0.00 %

+22.00 (+0.00%)

USD 2.38B
MVOL:LSE iShares Edge MSCI World M.. 0.00 % 0.00 %

+0.28 (+0.00%)

USD 2.38B
JP4H:XETRA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
HDLB ETRACS Monthly Pay 2xLeve.. 0.00 % 0.00 %

-0.17 (0.00%)

USD 0.01B
SCHJ Schwab 1-5 Year Corporate.. 0.00 % 0.00 %

-0.06 (0.00%)

USD 0.40B
HDIV 0.00 % 0.00 %

N/A

N/A
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

+0.07 (+0.00%)

USD 1.13B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.18 (0.00%)

USD 0.03B
GDOC Goldman Sachs ETF Trust 0.00 % 0.00 %

-0.04 (0.00%)

USD 0.02B
CSY9:XETRA Credit Suisse Index Fund .. 0.00 % 0.00 %

+0.04 (+0.00%)

USD 0.29B
WDMVO:SW Credit Suisse Index Fund .. 0.00 % 0.00 %

N/A

USD 0.28B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.24% 50% F 27% F
Dividend Return 0.95% 67% D+ 53% F
Total Return -18.29% 50% F 27% F
Trailing 12 Months  
Capital Gain -20.42% 56% F 34% F
Dividend Return 1.85% 25% F 28% F
Total Return -18.57% 56% F 34% F
Trailing 5 Years  
Capital Gain 0.77% 57% F 57% F
Dividend Return 19.47% 60% D- 80% B-
Total Return 20.24% 57% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 4.08% 78% C+ 60% D-
Dividend Return 7.99% 78% C+ 64% D
Total Return 3.91% 100% F 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 17.38% 67% D+ 79% B-
Risk Adjusted Return 45.99% 67% D+ 78% C+
Market Capitalization 98.10B 67% D+ 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.00 100% 56%
Price/Book Ratio 3.72 44% 29%
Price / Cash Flow Ratio 10.19 78% 25%
Price/Free Cash Flow Ratio 9.78 67% 27%
Management Effectiveness  
Return on Equity 2.39% 43% 62%
Return on Invested Capital 18.80% 80% 88%
Return on Assets 10.68% 100% 96%
Debt to Equity Ratio 101.93% 38% 23%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.